Myriad Genetics faces a sharp revenue decline and a failed Rule of 40 score, with late-cycle momentum risk and modest insider selling adding to the caution despite a strong earnings-surprise average.
Thesis pillars
- Rule Of Forty Failure→Stable
- Sharp Revenue Decline→Stable
- Late Cycle Momentum Risk↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Myriad Genetics, Inc. (MYGN) Stock Analysis
Inst Constrain edge
Healthcare · Diagnostics & Research
Sell if holding. Engine safety override at $5.50: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend.
Myriad Genetics develops and commercializes molecular diagnostic tests spanning hereditary cancer risk (MyRisk), companion diagnostics (BRACAnalysis CDx, MyChoice CDx), prostate and breast cancer prognostics (Prolaris, EndoPredict), prenatal screening (Prequel, Foresight,... Read more
Sell if holding. Engine safety override at $5.50: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Score 4.7/10, moderate confidence.
Passes 4/9 gates (clean insider activity, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and death cross (50MA < 200MA) and earnings proximity 6d<=7d. Suitability: aggressive.
About Myriad Genetics, Inc.
About Myriad Genetics, Inc.
Myriad Genetics sells its MyRisk hereditary cancer test across eleven cancer types and BRACAnalysis CDx, the only FDA-approved germline BRCA companion diagnostic for breast cancer with additional approvals in ovarian, pancreatic and prostate cancer, alongside MyChoice CDx, an HRD companion diagnostic validated in more than 20,000 patients. The company invested $106.8 million in research and development during 2025, down from $113.4 million in 2024, as it advanced newer tests including Precise MRD for molecular residual disease monitoring and FirstGene, a combined prenatal screen in early-access clinical study. Myriad primarily sells through its own sales force in the United States and Japan, expanding into Europe and Asia-Pacific through indirect distribution channels.
Myriad organizes its testing menu around three franchises: Oncology, spanning hereditary cancer risk, companion diagnostics and molecular residual disease monitoring; Women's Health, covering prenatal screening and carrier testing; and Mental Health, anchored by the GeneSight pharmacogenomic test used to guide antidepressant and ADHD medication selection. The company competes against Natera, Foundation Medicine, Caris Life Sciences, Tempus, LabCorp, Quest Diagnostics, Veracyte, Guardant Health, MDxHealth and NeoGenomics across its oncology and diagnostics businesses, differentiating through its brand reputation in hereditary cancer testing and community-medicine commercial reach. In August 2024, Myriad divested its EndoPredict business to Eurobio Scientific while retaining rights to sell EndoPredict as a laboratory-developed test outside the European Union, and the company plans to discontinue U.S. EndoPredict sales during the first half of 2026 as it shifts focus toward the Cancer Care Continuum.
Show full overview
Myriad frames molecular residual disease testing, through its Precise MRD assay, as a significant new growth opportunity, but the test remains newly commercialized and competes in a market where Natera and Guardant Health already hold established MRD franchises with longer clinical track records. Because Myriad's community-medicine commercial reach is its stated competitive advantage for winning MRD share rather than a first-mover technology edge, the ultimate size of this opportunity depends on physician adoption patterns that the 10-K does not yet quantify with test-volume or revenue-contribution figures specific to Precise MRD.
See also: Healthcare · Diagnostics & Research
From Myriad Genetics, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Material Events(8-K, last 90d)
- 2026-06-23Item 5.02LOWOn June 17, 2026 director Daniel M. Skovronsky notified the Board of his resignation, effective immediately, not due to any disagreement with the company's operations, policies or practices. No successor named.SEC filing →
- 2026-06-04Item 5.02LOWAt Myriad Genetics' 2026 annual meeting, stockholders approved a 4,000,000-share increase to the Employee Stock Purchase Plan and a new 2026 Equity Incentive Plan reserving 8,463,567 shares. Routine equity-compensation plan approvals.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Unprofitable operations — net margin -41.3%. Quality floor flags this regardless of sector context.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $5.50: Quality below floor (3.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.7/10. Specifically: Below-average business quality; Negative price momentum; Below long-term trend. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $5.22. Score 4.7/10, moderate confidence.
Take-profit target: $6.30 (-3.1% upside). Prior stop was $5.22. Stop-loss: $5.22.
Target reached (-3.1% upside); Quality below floor (3.2 < 4.0).
Myriad Genetics, Inc. trades at a P/E of N/A (forward 37.7). TrendMatrix value score: 7.3/10. Verdict: Sell.
15 analysts cover MYGN with a consensus score of 2.6/5. Average price target: $6.
What does Myriad Genetics, Inc. do?Myriad Genetics develops and commercializes molecular diagnostic tests spanning hereditary cancer risk (MyRisk),...
Myriad Genetics develops and commercializes molecular diagnostic tests spanning hereditary cancer risk (MyRisk), companion diagnostics (BRACAnalysis CDx, MyChoice CDx), prostate and breast cancer prognostics (Prolaris, EndoPredict), prenatal screening (Prequel, Foresight, FirstGene, SneakPeek) and pharmacogenomic mental-health testing (GeneSight). The company sells these tests to providers and health systems primarily in the United States and Japan, competing against Natera, Foundation Medicine, Caris Life Sciences, Tempus, LabCorp and Quest Diagnostics. Myriad spent $106.8 million on research